• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara’s Synchrogenix acquires ClinGenuity

Certara’s Synchrogenix acquires ClinGenuity

January 7, 2015
CenterWatch Staff

Synchrogenix, the regulatory and medical consultancy of Certara, a Princeton, N.J.-based global biosimulation technology-enabled drug development and drug safety consulting company, has acquired ClinGenuity, a Cincinnati-based artificial intelligence-assisted medical writing service. Their combined team now will include more than 200 regulatory and medical writers with experience in document development for the FDA, EMA and other global regulatory organizations.

“Large pharma and biotech companies increasingly are looking to outsource their regulatory and medical writing requirements,” said Edmundo Muniz, M.D., Ph.D., Certara CEO. “With the addition of ClinGenuity’s technology-enabled solution and experienced medical writers to our Synchrogenix team, we will be able to enhance process efficiencies and increase the offerings we can deliver to our clients.”

“With the addition of ClinGenuity’s automated redaction management capability to our existing transparency services, which include registration, disclosure documentation and clinical lay summary development, we can enable our clients to meet global transparency requirements efficiently,” said Synchrogenix CEO Kelley Kendle.

New European and U.S. clinical trial data transparency initiatives—such as EMA Policy 70, which went into effect in January 2015—are creating additional disclosure compliance requirements for pharma and biotech companies. For example, they now will need to redact and de-identify datasets in their clinical study reports and submission documents, produce research summaries suitable for a lay audience and publish their clinical study information publicly.

“We are excited to be joining Synchrogenix at this important stage in the industry’s growth; it will enable us to expand the depth and breadth of services that we can offer to our clients as they seek to meet these new regulatory requirements,” said Kleeman, who will become president of Synchrogenix.

ClinGenuity offers a range of medical writing services including development of clinical study reports, protocols and submissions, medical letters and commercial documents such as peer-reviewed articles. It also has transparency/disclosure products including redaction, lay summary and data mining services.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing